Researchers at the Wellcome Sanger Institute and their global collaborators have unveiled the first comprehensive cellular blueprint of human skeletal…
Read More
EASD 2026: Cagrisema Weight Loss Holds at Submaximal Doses in REDEFINE 1 Analysis
The landscape of metabolic disease management continues to undergo a profound transformation as clinical investigators unveil nuanced data regarding next-generation…
Read More
The space rock holds clues to the origin of Earth’s oceans and organics
A celestial visitor that captivated New York City with its fiery descent and ultimately landed on a New Jersey rooftop…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape underwent a significant reordering in fiscal year 2025, as revealed by the latest "Pharma 50"…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025.
The pharmaceutical industry witnessed a significant shift in its commercial landscape during Fiscal Year 2025, with Merck’s oncology powerhouse, Keytruda…
Read More
A Hidden Housekeeping Gene Holds the Key to Enhanced Fruit Quality Without Compromising Plant Growth
The pursuit of superior fruit quality—brighter colors, more enticing aromas, and richer nutritional profiles—has long been a cornerstone of agricultural…
Read More
Light makes plants stronger but also holds them back
The intricate dance between light and plant development, a cornerstone of life on Earth, continues to reveal its complexities to…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
Merck’s immunotherapy blockbuster, Keytruda (pembrolizumab), maintained its dominant position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording…
Read More
Pharma 50: Keytruda Holds Top Brand Slot, But Tirzepatide and Semaglutide Have Already Passed It at the Molecule Level in FY2025
Merck’s Keytruda (pembrolizumab) maintained its formidable position as the pharmaceutical industry’s leading brand in Fiscal Year 2025, recording an impressive…
Read More
Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025
The pharmaceutical industry’s financial landscape is undergoing a significant transformation, marked by the continued brand dominance of Merck’s Keytruda (pembrolizumab)…
Read More
